Condition: Duodenum Cancer · Familial Adenomatous Polyposis · Duodenal Polyposis · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Duodenal cancer is the leading cause of cancer-related mortality in patients with familial adenomatous polyposis (FAP), yet the current Spigelman staging system provides limited predictive accuracy for advanced neoplasia. The DRACO study (Duodenal Risk Assessment in adenomatous polyposis Coli -Oncogene) is a multicenter, STROBE- and CONSORT-compliant cohort study that analyzes upper endoscopies from genetically confirmed FAP patients across independent cohorts to develop, validate, and externally test two multivariable risk models.
This description comes directly from the study's public registry record.
Marco Vitellaro, M.D. · +393480197920 · marco.vitellaro@istitutotumori.mi.it
Always discuss trial participation with your own doctor first.
| IRCCS Ospedale San Raffaele | Milan, MI, Italy | Recruiting |
| Fondazione IRCCS Istituto Nazionale dei Tumori | Milan, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07199127